Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Abstract The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objec...

Full description

Bibliographic Details

Published in:	EMBO Molecular Medicine
Main Authors:	Miren Zuazo, Hugo Arasanz, Gonzalo Fernández‐Hinojal, Maria Jesus García‐Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, Maria Jose Lecumberri, Angela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors
Format:	Article
Language:	English
Published:	Springer Nature 2019-06-01
Subjects:	B7‐H1 biomarker immunotherapy lung cancer PD‐1/PD‐L1
Online Access:	https://doi.org/10.15252/emmm.201910293